T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo

Despite advances in the development of targeted therapies for acute myeloid leukemia (AML), most patients relapse. For that reason, it is still necessary to develop novel therapies that improve treatment effectiveness and overcome drug resistance. We developed T22-PE24-H6, a protein nanoparticle tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Núñez, Yáiza, Garcia-León, Annabel, Falgàs, Aïda, Serna, Naroa, Sánchez-García, Laura, Garrido, Ana, Sierra, Jorge, Gallardo, Alberto, Unzueta, Ugutz, Vázquez, Esther, Villaverde, Antonio, Mangues, Ramon, Casanova, Isolda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054149/
https://www.ncbi.nlm.nih.gov/pubmed/36986589
http://dx.doi.org/10.3390/pharmaceutics15030727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054149/
https://www.ncbi.nlm.nih.gov/pubmed/36986589
http://dx.doi.org/10.3390/pharmaceutics15030727

Ejemplares similares